Wei Yang

Dr. Wei Yang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Drug Delivery
Verified
Journal Article
Open access
WYWei Yang
Wei Yang
BJBing-Hui Jin
Bing-Hui Jin
YCYa-Jing Chen
Ya-Jing Chen
CCChang Cao
Chang Cao
JZJia-Zhen Zhu
Jia-Zhen Zhu
FLFanzhu Li
Fanzhu Li
Our previous work indicates the lymphatic network and perivascular spaces or tissues might be involved in the facial intradermal brain-targeted delivery of Evans blue (EB). In this article, we presented the detailed involvement of both, and the linkage between lymphatic network and perivascular spaces or tissues. The in-vivo imaging, the trigeminal transection and immunohistochemistry were used. In-vivo imaging indicated intradermal injection in the mystacial pad (i.d.) delivered EB into the brain at 2-, 6- and 24 h, while intranasal injection (i.n.) delivered EB into the rostral head and intravenous injection (i.v.) diffused EB weakly into the brain. Trigeminal perineurial and epineurial EB occurred along the perivascular spaces or tissues and along brain vessels. EB diffused into the lymphatic vessels and submandibular lymph nodes. Moreover, perineurial and epineurial EB co-located or overlaid with Lyve1 immuno-reactivity and VEGF antibody, and lymphatic network connected with perivascular spaces or tissues, suggesting lymphatic system-perivascular spaces might involve in the EB delivery with i.d. The trigeminal transection reduced the trigeminal epineurial and perineurial EB and brain EB along vessels. EB diffused in the fasciculus and the perineurium, blood and lymphatic vessels in the mystacial pad, mystacial EB overlaid VEGF or Lyve1 antibody. In summary, the dermal-trigeminal-brain perivascular spaces or tissues and the linkage to the lymphatic network mediated the intradermal brain-targeted delivery.

6 August 2020 in Chinese Neurosurgical Journal
Verified
Journal Article
Open access
PDF file
WYWei Yang
Wei Yang
MGMing Ge
Ming Ge
CCChenghao Chen
Chenghao Chen
QZQi Zeng
Qi Zeng
Background Pleural-subarachnoid fistula (PSF) is a rare disease that is difficult to diagnose and treat. Secondary intracranial hypertension and the treatment are seldom mentioned previously among PSF. Case presentation A 1-year-old boy diagnosed PSF developed into secondary intracranial hypertension after conservative treatment. He was finally cured by down-step treatment of mannitol, avoiding form ventricle-peritoneal shunt. Then, we reviewed the literature of pleural-subarachnoid fistula. Fifty-six cases have been reported so far. Most of the cases (51.8%) were caused by surgery; only 17.9% were caused by car accidents. Regarding the treatment, half of the cases cured by surgery and the other by conservative measures. Our case is the first one involving secondary intracranial hypertension and cured by down-step treatment of mannitol. Conclusions A comprehensive examination should be performed before the treatment to avoid any inappropriate medical strategies. Secondary acute intracranial hypertension may be cured by down step treatment of mannitol, evading from the long-term ventriculoperitoneal shunt.

15 September 2025 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
XPXiaojiao Peng
Xiaojiao Peng
ZZZhuo Zhi
Zhuo Zhi
XCXinyi Chai
Xinyi Chai
HZHong Zhang
Hong Zhang
YCYingjie Cai
Yingjie Cai
MGMing Ge
Ming Ge
Background: Cerebellar Mutism Syndrome (CMS) is a significant neurological complication following posterior fossa tumor surgery in children. The pathophysiological mechanisms of CMS remain elusive, and there is a growing interest in the potential influence of sex on its incidence. This study aims to evaluate sex as an independent risk factor for the development of CMS.Methods: A retrospective cohort study of 385 pediatric patients who underwent posterior fossa tumor surgery at Beijing Children's Hospital (2013–2024) was conducted. Comprehensive demographic, clinical, and pathological data were collected. Statistical analysis involved Chi-square tests for categorical variables, Kruskal–Wallis tests for non-parametric comparisons among groups, and logistic regression to identify independent predictors of CMS.Results: CMS occurred in 29.9% of all cases, with annual incidence ranging from 14.3% to 37.9%. Medulloblastoma was the most common pathology (38.4%), with a median maximal tumor diameter of 47.2 mm. Tumors were predominantly located at the midline (68.1%), and gross total resection was achieved in 86.3% of patients. Male patients exhibited a significantly higher incidence of CMS compared to females (73.0% vs. 53.0%, p = 0.003). Independent risk factors for CMS included male sex [OR 2.25; 95% CI (1.30–3.70)], midline tumor location [OR 7.47; 95% CI (2.79–19.98)], and medulloblastoma diagnosis [OR 2.11; 95% CI (1.24–3.59)].Conclusion: This study indicates a notable male predominance in CMS occurrence, suggesting the existence of sex-specific differences in cerebellar function and language development. These findings highlight the need for heightened monitoring and tailored interventions for male patients undergoing posterior fossa tumor surgery and suggest a potential biological basis for sex-specific differences in cerebellar function and vulnerability to surgical injury.Importance of the study: This study provides critical insights into the significant role of sex as an independent risk factor for Cerebellar Mutism Syndrome (CMS) following posterior fossa tumor surgeries in pediatric patients. By identifying male sex, midline tumor location, and medulloblastoma pathology as independent predictors, this research addresses a gap in understanding sex-based disparities in CMS development. These findings suggest potential gender-specific differences in cerebellar and language development, offering a foundation for future translational research and targeted clinical strategies. The results emphasize the need for heightened monitoring and tailored interventions, especially for male patients, to mitigate CMS risk and improve surgical outcomes in pediatric neurosurgery.

1 June 2023 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
WYWei Yang
Wei Yang
WMWenping Ma
Wenping Ma
JHJiansong Huang
Jiansong Huang
YCYingjie Cai
Yingjie Cai
XPXiaojiao Peng
Xiaojiao Peng
MGMing Ge
Ming Ge

23 May 2025 in Children
Verified
Journal Article
Open access
PDF file
XCXinyi Chai
Xinyi Chai
WYWei Yang
Wei Yang
YCYingjie Cai
Yingjie Cai
XPXiaojiao Peng
Xiaojiao Peng
XQXuemeng Qiu
Xuemeng Qiu
MGMing Ge
Ming Ge
Objective: To develop and validate a composite model that combines lesion–symptom mapping (LSM), radiomic information, and clinical factors for predicting cerebellar mutism syndrome in pediatric patients suffering from posterior fossa tumors. Methods: A retrospective analysis was conducted on a cohort of 247 (training set, n = 174; validation set, n = 73) pediatric patients diagnosed with posterior fossa tumors who underwent surgery at Beijing Children’s Hospital. Presurgical MRIs were used to extract the radiomics features and voxel distribution features. Clinical factors were derived from the medical records. Group comparison was used to identify the clinical risk factors of CMS. Combining location weight, radiomic features from tumor area and the significant intersection area, and clinical variables, hybrid models were developed and validated using multiple machine learning models. Results: The mean age of the cohort was 4.88 [2.89, 7.78] years, with 143 males and 104 females. Among them, 73 (29.6%) patients developed CMS. Gender, location, weight, and five radiomic features (three in the tumor mask area and two in the intersection area) were selected to build the model. The four models, KNN model, GBM model, RF model, and LR model, achieved high predictive performance, with AUCs of 0.84, 0.83, 0.81, and 0.87, respectively. Conclusions: CMS can be predicted using MRI features and clinical factors. The combination of radiomics and tumoral location weight could improve the prediction of CMS.

20 March 2025 in Children
Verified
Journal Article
Open access
PDF file
JCJiashu Chen
Jiashu Chen
WYWei Yang
Wei Yang
ZYZesheng Ying
Zesheng Ying
PYPing Yang
Ping Yang
YLYuting Liang
Yuting Liang
MGMing Ge
Ming Ge
Background and Purpose: Medulloblastoma (MB) represents the predominant intracranial neoplasm observed in pediatric populations, characterized by a five-year survival rate ranging from 60% to 80%. Anticipating the prognostic outcome of medulloblastoma in children prior to surgical intervention holds paramount significance for informing treatment modalities effectively. Radiomics has emerged as a pervasive tool in both prognostic anticipation and therapeutic management across diverse tumor spectra. This study aims to develop a radiomics-based prediction model for the prognosis of children with MB and to validate the contribution of radiomic features in predicting the prognosis of MB when combined with clinical features. Materials and Methods: Patients diagnosed with medulloblastoma at our hospital from December 2012 to March 2022 were randomly divided into a training cohort (n = 40) and a test cohort (n = 41). Regions of interest (ROIs) were manually drawn on T1-weighted images (T1WI) along the boundary of the tumor, and radiomic features were extracted. Radiomic features related to survival prognosis were selected and used to construct a radiomics model. The patients were classified into two different risk stratifications according to the Risk-score calculated from the radiomics model. The log-rank test was used to test the difference in survival between the two stratifications to verify the classification value of the radiomics model. Clinical features related to the prognosis were used to construct a clinical model or clinical–radiomics model together with the radiomic features. Then, the clinical model, radiomics model, and clinical–radiomics model were compared to validate the improvement of radiomics in predicting the prognosis of medulloblastoma. The performance of the three models was evaluated with the C-index and the time-dependent AUC. Overall survival (OS) was defined as the time from receiving the operation to death or last follow-up. Results: A total of 81 children were included in this study. A total of five prognostic radiomic features were selected. The radiomics model could discriminate different risk hierarchies with good performance power in the training and testing datasets (training set p= 0.0009; test set p = 0.0286). Six clinical features associated with prognosis (duration of disease, risk hierarchy, dissemination, radiology, chemotherapy, and last postoperative white blood cell (WBC) level in CSF) were selected. The radiomic–clinical molecular features had better predictive value for OS (C-index = 0.860; Brier score: 0.087) than the radiomic features (C-index = 0.762; Brier score: 0.073) or clinical molecular characteristics (C-index = 0.806; Brier score: 0.092). Conclusions: Radiomic features based on T1-weighted imaging have predictive value for pediatric medulloblastoma. Radiomics has incremental value in predicting the prognosis of MB, and clinical–radiomics models have a better predictive effect than clinical models.